Patents by Inventor Olivier Boyer

Olivier Boyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TREATING MYOSITIS USING FCRN ANTAGONISTS
    Publication number: 20250084171
    Abstract: Provided herein are methods of treating myositis using an effective amount of a human neonatal Fc receptor (FcRn) antagonist. FcRn antagonists for use in the treatment of myositis and for use in the manufacture of a medicament for the treatment of myositis are also provided herein.
    Type: Application
    Filed: August 21, 2024
    Publication date: March 13, 2025
    Inventors: Sebastian Paul van der Woning, Olivier Boyer, Laurent Drouot
  • METHODS FOR DETECTING THE PRESENCE OF CORONAVIRUS-SPECIFIC ANTIBODIES IN A SUBJECT
    Publication number: 20230194528
    Abstract: Coronaviridae is a family of enveloped, positive-sense, single-stranded RNA viruses. The viral genome is 26-32 kilobases in length. In late December 2019, a new betacoronavirus SARS-CoV-2 has emerged in Wuhan China. The World Health Organization has named the severe pneumonia caused by this new coronavirus COVID-19 (for Corona Virus Disease 2019, WHO, 2020). To fight against the COVID-19 pandemic in a long term, in addition to the containment measures implemented in many countries, reliable diagnostic methods are highly desirable. In particular, the development and availability of tests for the detection and quantification of anti-SARS-CoV-2 antibodies in subjects with COVID-19 is of strong diagnostic interest. The present fulfils this need. In particular, the inventors developed an 15 Adressable Laser Beads ImmunoAssay (ALBIA) method based on the use of particles conjugated with a coronaviral polypeptides (S1,S2, S2?, N, PL-Pro).
    Type: Application
    Filed: April 13, 2021
    Publication date: June 22, 2023
    Inventors: Olivier BOYER, Laurent DROUOT
  • INFLAMMATORY DISEASE TREATMENT WITH COMPLEMENT INHIBITORS
    Publication number: 20220257697
    Abstract: The present disclosure provides methods of treating inflammatory indications with complement inhibitor compounds and compositions. Included are compounds and methods of treating neuromuscular inflammatory indications, such as Immune-Mediated Necrotizing Myopathy.
    Type: Application
    Filed: June 4, 2020
    Publication date: August 18, 2022
    Inventors: Petra DUDA, Ramin FARZANEH-FAR, Alonso RICARDO, Camil SAYEGH, Nanqun ZHU, Douangsone D. VADYSIRISACK, Olivier BOYER, Laurent DROUOT
  • METHODS FOR PREDICTING RHEUMATOID ARTHRITIS TREATMENT RESPONSE
    Publication number: 20160123992
    Abstract: The invention relates to methods and means for predicting rheumatoid arthritis treatment response.
    Type: Application
    Filed: June 10, 2014
    Publication date: May 5, 2016
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE DE ROUEN, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, CENTRE HOSPITALIER UNIVERSITAIRE DE ROUEN
    Inventors: Olivier Vittecoq, Thierry Lequerre, Pascal Cosette, Olivier Boyer, Xavier Le Loët, Julie Hardouin, Antoine Obry
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
    Publication number: 20140086895
    Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of autoimmune diseases, especially rheumatoid arthritis. More particularly, the present invention relates to an a-enolase polypeptide for use in the prophylactic treatment of an autoimmune disease in a subject in need thereof.
    Type: Application
    Filed: May 10, 2012
    Publication date: March 27, 2014
    Applicants: Universite de Rouen, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Olivier Vittecoq, Céline Derambure, Thierry Lequerre, Olivier Boyer, Francois Tron, Xavier Le Loet, Daniêle Gilbert
  • CD4 gene regulatory sequences specifically expressed in mature T cells
    Patent number: 6333171
    Abstract: The present invention relates to compositions and methods for the expression of nucleic acids or polypeptides into mature T lymphocytes. The invention relates more specifically to methods of selective gene expression into mature T lymphocytes, based on CD4-derived regulatory sequences, such as CD4-derived enhancer sequences. The invention is particularly suited for regulating gene expression into mature T lymphocytes in vitro, ex vivo or in vivo, upon genetic modification of hematopoietic precursors and maturation thereof.
    Type: Grant
    Filed: January 16, 1998
    Date of Patent: December 25, 2001
    Assignee: Universite Pierre et Marie Curie
    Inventors: David Klatzmann, Patrick Salmon, Olivier Boyer